Technical Analysis for SAGE - Sage Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 2.39% | |
| Gapped Up | Strength | 2.39% | |
| Oversold Stochastic | Weakness | 2.39% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | -1.44% | |
| New 52 Week Closing Low | Bearish | 0.76% | |
| Down 3 Days in a Row | Weakness | 0.76% | |
| Down 4 Days in a Row | Weakness | 0.76% | |
| Down 5 Days in a Row | Weakness | 0.76% |
| Alert | Time |
|---|---|
| Up 3% | about 1 hour ago |
| Up 2% | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 3 hours ago |
| Up 1% | about 3 hours ago |
| Down 2 % | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 06/10/2024
Sage Therapeutics, Inc. Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Drugs Clinical Development Pharmacology Central Nervous System Disorders Nervous System Disorders Toxicology Seizure Antidepressants Gabaa Receptor Positive Allosteric Modulators Adjunctive Therapy Anticonvulsants Neurosteroids Status Epilepticus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 59.98 |
| 52 Week Low | 10.92 |
| Average Volume | 1,028,251 |
| 200-Day Moving Average | 20.33 |
| 50-Day Moving Average | 16.20 |
| 20-Day Moving Average | 13.03 |
| 10-Day Moving Average | 12.58 |
| Average True Range | 0.89 |
| RSI (14) | 30.07 |
| ADX | 36.69 |
| +DI | 17.68 |
| -DI | 28.83 |
| Chandelier Exit (Long, 3 ATRs) | 13.07 |
| Chandelier Exit (Short, 3 ATRs) | 13.59 |
| Upper Bollinger Bands | 14.49 |
| Lower Bollinger Band | 11.57 |
| Percent B (%b) | 0.05 |
| BandWidth | 22.37 |
| MACD Line | -1.19 |
| MACD Signal Line | -1.24 |
| MACD Histogram | 0.0517 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.05 | ||||
| Resistance 3 (R3) | 13.19 | 12.88 | 12.82 | ||
| Resistance 2 (R2) | 12.88 | 12.54 | 12.81 | 12.75 | |
| Resistance 1 (R1) | 12.30 | 12.33 | 12.15 | 12.16 | 12.67 |
| Pivot Point | 11.99 | 11.99 | 11.92 | 11.92 | 11.99 |
| Support 1 (S1) | 11.41 | 11.65 | 11.26 | 11.27 | 10.75 |
| Support 2 (S2) | 11.10 | 11.44 | 11.03 | 10.67 | |
| Support 3 (S3) | 10.52 | 11.10 | 10.60 | ||
| Support 4 (S4) | 10.38 |
